We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 09, 2020

Adjuvant Trastuzumab for 6 Months Noninferior to 1 Year in Patients With HER2-Positive Breast Cancer

The Breast


Additional Info

The Breast
Do All Patients With HER2 Positive Breast Cancer Require One Year of Adjuvant Trastuzumab? A Systematic Review and Meta-Analysis
Breast 2020 Oct 21;[EPub Ahead of Print], P Stewart, P Blanchette, PS Shah, XY Ye, RG Boldt, R Fernandes, T Vandenberg, J Raphael

Further Reading